Accelerated Pharma (Accelerated Pharma) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Accelerated Pharma's annualized Gross Profit for the quarter that ended in Mar. 2017 was $0.00 Mil. Accelerated Pharma's average Total Assets over the quarter that ended in Mar. 2017 was $0.17 Mil. Therefore, Accelerated Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2017 was 0.00%.

Accelerated Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Accelerated Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Gross-Profit-to-Asset % Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Gross-Profit-to-Asset %

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Gross-Profit-to-Asset % falls into.

Accelerated Pharma Gross-Profit-to-Asset % Calculation

Accelerated Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2016 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2016 )	/	( (Total Assets (A: Dec. 2015 )	+	Total Assets (A: Dec. 2016 ))	/ count )
	=	0	/	( (0.766	+	0.147)	/ 2 )
	=	0	/	0.4565
	=	0.00 %

Accelerated Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2017 )	/	( (Total Assets (Q: Dec. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
	=	0	/	( (0.147	+	0.198)	/ 2 )
	=	0	/	0.1725
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2017) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Accelerated Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines